S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:KRYSKrystal Biotech Stock Price, Forecast & News

$40.12
-1.06 (-2.57 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$40.00
Now: $40.12
$42.56
50-Day Range
$39.91
MA: $41.97
$45.48
52-Week Range
$31.89
Now: $40.12
$66.85
Volume149,700 shs
Average Volume172,304 shs
Market Capitalization$697.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.01
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Read More
Krystal Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KRYS
CUSIPN/A
Phone412-586-5830

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$11.72 per share

Profitability

Net Income$-19,090,000.00

Miscellaneous

Employees37
Market Cap$697.53 million
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
$40.12
-1.06 (-2.57 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

How has Krystal Biotech's stock price been impacted by COVID-19?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KRYS shares have decreased by 19.6% and is now trading at $40.12.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Krystal Biotech?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Krystal Biotech
.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Krystal Biotech
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech Inc (NASDAQ:KRYS) posted its earnings results on Monday, August, 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08.
View Krystal Biotech's earnings history
.

What price target have analysts set for KRYS?

7 brokerages have issued 12-month price objectives for Krystal Biotech's stock. Their forecasts range from $60.00 to $100.00. On average, they anticipate Krystal Biotech's share price to reach $79.80 in the next twelve months. This suggests a possible upside of 98.9% from the stock's current price.
View analysts' price targets for Krystal Biotech
.

What are Wall Street analysts saying about Krystal Biotech stock?

Here are some recent quotes from research analysts about Krystal Biotech stock:
  • 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (5/8/2020)
  • 2. Cowen Inc analysts commented, "On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated." (8/15/2019)

Has Krystal Biotech been receiving favorable news coverage?

Headlines about KRYS stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Krystal Biotech earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Krystal Biotech
.

Are investors shorting Krystal Biotech?

Krystal Biotech saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 1,490,000 shares, a decline of 12.9% from the January 31st total of 1,710,000 shares. Based on an average daily trading volume, of 156,200 shares, the short-interest ratio is currently 9.5 days. Approximately 13.7% of the company's shares are sold short.
View Krystal Biotech's Short Interest
.

Who are some of Krystal Biotech's key competitors?

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Pfizer (PFE), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (VBIV), Fortinet (FTNT) and Inovio Pharmaceuticals (INO).

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:
  • Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)
  • Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)
  • Ms. Pooja Agarwal, VP of Product Devel. (Age 40)
  • Mr. Antony A. Riley, Chief Financial Officer (Age 51)
  • Ms. Gloria Lin, Accounting Mang.

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (1.64%), Victory Capital Management Inc. (1.60%), Bank of New York Mellon Corp (0.34%), Blair William & Co. IL (0.29%), Nicholas Investment Partners LP (0.23%) and Hudson Bay Capital Management LP (0.20%). Company insiders that own Krystal Biotech stock include Daniel Janney, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends for Krystal Biotech
.

Which institutional investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP, Blair William & Co. IL, Alps Advisors Inc., Bank of New York Mellon Corp, Chartwell Investment Partners LLC, and Mutual of America Capital Management LLC. Company insiders that have sold Krystal Biotech company stock in the last year include Daniel Janney, Krish S Krishnan, and Suma Krishnan.
View insider buying and selling activity for Krystal Biotech
.

Which institutional investors are buying Krystal Biotech stock?

KRYS stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Goldman Sachs Group Inc., Hudson Bay Capital Management LP, SG Americas Securities LLC, Bessemer Group Inc., HighMark Wealth Management LLC, Rafferty Asset Management LLC, and Swiss National Bank.
View insider buying and selling activity for Krystal Biotech
.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $40.12.

How big of a company is Krystal Biotech?

Krystal Biotech has a market capitalization of $697.53 million. The company earns $-19,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Krystal Biotech employs 37 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.